Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon alfa-2b Combined with NAs in Compensated HBV-Related Liver Cirrhosis
NCT07183293Not yet recruiting
- Sponsor
- Xiamen Humanity Hospital
- Start
- Oct 2025
- Primary completion
- Mar 2027
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Randomised, open-label trial of peginterferon alfa-2b in hepatitis B (HBV) and Liver cirrhosis (LC) (2 arms), sponsored by Xiamen Humanity Hospital. Primary endpoint: Change in liver histological score from baseline. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
hepatitis B (HBV)Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT07183293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07183293.